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Jordi Matias-Guiu, MD, Joan Bigorra, MD, Pedro Gil, MD, Antonio Carbonell, MD,
and Jose M. Martiriez-Lage, MD
Nimodipine is a 1,4-dihydropyridine derivative that shows a preferential cerebrovascular
activity in experimental animals. Clinical data suggest that nimodipine has a beneficial effect
on the neurologic outcome of patients suffering an acute ischemic stroke. Our double-blind
placebo-controlled multicenter trial was designed to assess the effects of oral nimodipine on the
mortality rate and neurologic outcome of patients with an acute ischemic stroke. One hundred
sixty-four patients were randomly allocated to receive either nimodipine tablets (30 mg q.i.d.)
or identical placebo tablets for 28 days. Treatment was always started <48 hours after the acute
event. The Mathew Scale, slightly modified by Gelmers et al, was used for neurologic
assessment. Mortality rate and neurologic outcome after 28 days were used as evaluation
criteria. We considered 123 patients to be valid for the analysis of efficacy. Mortality rates did
not differ significantly between groups. Neurologic outcome after 28 days of therapy did not
differ between groups. However, when only those patients most likely to benefit from any
intervention (Mathew Scale sum score of <65 at baseline) were analyzed separately in post
hoc-defined subgroups, the nimodipine-treated subgroup showed a significantly better neuro-
logic outcome. This result suggests that some patients with acute ischemic stroke will benefit
from treatment with nimodipine tablets. (Stroke 1990;21:1023-1028)
Although it is one of the leading causes ofdeath and disability in the Western world,the treatment of cerebral ischemic infarc-
tion remains controversial. This controversy is mainly
due to the fact that most therapeutic measures used
in many centers, even those therapies used on a
routine basis, have not been fully evaluated in ade-
quate controlled clinical trials.1
Although the sequence of events that take place in
cerebral ischemia is not completely understood, some
key factors involve the release of neurotransmitters
resulting from depolarization and the presynaptic
influx of Ca2+.2 This allows speculation that pharma-
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cologic intervention aimed at reducing the presynap-
tic and postsynaptic influx of Ca2+ could be beneficial
in patients with acute cerebral ischemia.
Nimodipine is a calcium antagonist derived from
the 1,4-dihydropyridine ring with a preferential
cerebrovascular action.3 Experimental studies have
shown that the administration of nimodipine after
complete cerebral ischemia improves neurologic out-
come in dogs4 and primates.5 Studies of cerebral
blood flow in patients with vasospasm after subarach-
noid hemorrhage and patients with ischemic cerebral
infarction suggest that nimodipine increases hemi-
spheric blood flow in a dose-dependent manner
without resulting in a steal phenomenon.6 The results
of an open study7 and the results of a placebo-
controlled trial reported up to now8 show that treat-
ment with nimodipine starting early after the onset of
cerebral ischemic infarction favorably alters the neu-
rologic and possibly the functional8 outcome of such
patients.
The aim of our study was to assess the influence of
nimodipine on two predefined end points: the 28-day
mortality rate and the neurologic outcome after 28
days of in-hospital treatment.
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Subjects and Methods
Four departments of neurology in Spain were
responsible for recruiting, treating, and evaluating
patients admitted for acute ischemic stroke between
August 1984 and June 1987. The study protocol was
approved by the clinical trial committees of the
centers and by the Regulatory Board for Drugs and
Health Care Products of the Spanish Ministry of
Health before the start of the trial.
Patients >44 years old with acute ischemic stroke
in the internal carotid artery territory, as diagnosed
by clinical examination, were qualified for entry into
the trial if they were seen <48 hours after stroke
onset. The clinical diagnosis always had to be con-
firmed by an early computed tomogram performed
during the first 3 days after qualifying.
Patients with acute myocardial infarction, renal
failure, liver failure, severe systemic infections,
poorly controlled diabetes mellitus, systolic arterial
blood pressure of < 100 mm Hg, or terminal malig-
nancy were excluded from the study. Patients whose
neurologic deficit recovered completely within 24
hours (transient ischemic attack), those with stroke-
in-evolution, and those in coma were considered
ineligible for the study. All patients with brain lesions
other than infarction (such as subarachnoid hemor-
rhage and intracerebral hemorrhage) or special
causes for the stroke (such as complicated migraine)
were also excluded. Informed consent was obtained
in every case from the patient or a responsible
relative.
Patients entered into the study were randomly
allocated to receive either oral nimodipine, one
30-mg tablet every 6 hours, or an identical placebo
tablet. Treatment was started in all cases <48 hours
after the onset of clinical manifestations of acute
ischemic stroke and continued during 28 days in the
hospital. The study protocol allowed the administra-
tion of prophylactic heparin (5,000 IU b.i.d.) and
agents considered to be medically indicated in cere-
bral edema as well as cardiovascular drugs other than
calcium antagonists and antibiotic or anxiolytic med-
ications when needed.
The Mathew Scale,9 as slightly modified by Gelm-
ers et al,8 was used as the main criterion for assessing
the neurologic outcome of the patients. Neurologic
deficit was rated at entry into the study (baseline)
and after 1, 3, 5, 7, 14, 21, and 28 days of treatment.
A Mathew Scale sum score of <65 indicates
moderate-to-very severe deficit.
For the analysis of homogeneity of the groups we
used Student's t test for age, the Mann-Whitney test
for baseline Mathew Scale scores, and the ) ? test for
sex differences. Mortality was compared using sur-
vival tables.
When comparing changes in neurologic deficit, it is
important to take into account that the Mathew Scale
is an ordinal one with upper and lower limits. The
greatest possible increase in the Mathew Scale score
depends on the baseline score; therefore, a relative
TABLE 1. Stroke Patients Excluded From Efficacy Analysis by
Treatment Group
Reason for exclusion
Treatment initiated too late
Wrong diagnosis and concomitant
disease not allowed
Brain computed tomogram not
available
Coma
Insufficient duration of treatment
and/or lost to follow-up
Treatment
Nimodipine
5
7
2
3
6
group
Placebo
4
5
3
1
5
change in the neurologic deficit is defined as x=
(yt-_y0)-r(100-y0)xl00% for improvements (i.e.,
yt>_V0) and x=(yt-y0)+yoxl00% for deteriorations
(i.e., yt<yo), where _yo=Mathew .Scale sum score at
baseline and yt=Mathew Scale sum score after 28
days. Modification of the denominator for improve-
ments and deteriorations is necessary to get the same
range of possible changes between 100% and -100%
independent of the individual's baseline score. A
similar method was used for each item of the Mathew
Scale. For those patients with only a baseline score
(i.e., patient withdrew from the study), the numerator
was calculated as 0 because no other information on
the clinical course of the patient was available. Rela-
tive reduction of neurologic deficit was analyzed using
a nonparametric two-sample test (Breslow statistic).
Results
We entered 164 patients, of whom 81 (43 men and
38 women) received nimodipine; the remaining 83
patients (43 men and 40 women) received placebo.
The groups were well matched for age, height, and
weight distributions. The average age was 71.9
(range, 45-92) years in the nimodipine group and
72.3 (range, 50-92) years in the placebo group.
Of the 164 patients entered into the study, 41 were
excluded blindly from the efficacy analysis by the
Review Committee (Table 1); the other 123 (58
receiving nimodipine and 65 receiving placebo) were
considered valid for the efficacy analysis (Table 2).
No significant differences were observed between
groups for severity of the initial neurologic deficit
according to the Mathew Scale sum scores at baseline
(Table 3). Mortality rate after 28 days was 10.3% (six
of 58) in the nimodipine group and 15.4% (10 of 65)
in the placebo group. No sex-specific differences in
mortality rates were detected. The causes of death by
clinical findings in both groups are shown in Table 4.
Including all 164 patients randomized (intention-
to-treat analysis), mortality was 14.8% (12 of 81) in
the nimodipine group and 16.9% (14 of 83) in the
placebo group.
In an exploratory analysis, patients with moderate-
to-very-severe neurologic deficit at baseline were
looked at separately (Table 5). Among these patients,
mortality rate was 12.5% (six of 48) in the nimodipine
subgroup and 20.8% (10 of 48) in the placebo sub-
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TABLE 2. Characteristics of 123 Stroke Patients Considered Valid
for Efficacy Analysis by Treatment Group
Treatment group
Characteristic
Nimodipine
(n=58)
Placebo
(II=65)
Age (mean±SD yr)
Sex
Female
Male
Location of lesion
Left hemisphere
Right hemisphere
Risk factors
Hypertension
Diabetes mellitus
Cardiac disorders
71.8±10.0
25
33
38
20
16
8
40
71.9±10.1
28
37
38
27
14
13
35
Data are number of patients unless noted.
group (difference not significant); all patients who
died during the treatment period had a Mathew Scale
sum score of <65 at baseline.
There was no significant difference between
groups in relative change in neurologic deficit for all
164 randomized patients (intention-to-treat analysis,
/?=0.31) or for the 123 patients valid for efficacy
analysis (/>=0.15, Figure 1). In the exploratory analy-
sis, however, there was a significant difference (calcu-
lated by the Breslow statistic) in favor of nimodipine
(p<0.025, Figure 2). Approximately 40% of the
nimodipine-treated patients had a reduction of neu-
rologic deficit of at least 50%, whereas < 10% of the
placebo-treated patients showed such a reduction.
A descriptive analysis of the relative change for
each item of the Mathew Scale was also performed for
the 123 patients valid for efficacy analysis. Those items
TABLE 3. Severity of Initial Neurologic Deficit in 123 Stroke
Patients Considered Valid for Efficacy Analysis as Baseline
Mathew Scale Sum Score
Treatment group
Severity Score
Nimodipine
(n=58)
Placebo
(«=65)
Mild >65 10
Moderate to very severe <65 48
17
48
Data are number of patients.
TABLE 4. Causes of Death Among 164 Stroke Patients Random-
ized by Treatment Group
Treatment group
Cause of death
Bronchopneumonia, pulmonary
embolism
Heart failure, myocardial infarction
Brain edema
Septicemic shock
Nimodipine
(n=81)
4
2
5
1
Placebo
(n=83)
4
2
8
0
Cumulative
proportion
of patients
[%]
100-.
90
80-
70-
60-
50-
40-
30-
20-
10-
+100
normal
75 50
4
25 0 -25 -50 ^75
unchanged
improvement deterioration >.
-100
dead
Data are number of patients.
FIGURE 1. Cumulative frequency diagram of relative change
in neurologic deficit for 123 stroke patients valid for efficacy
analysis. —, Nimodipine group (n=58); , placebo group
(n=65).
showing the greatest differences between groups are
outlined below.
Thirty-nine patients in the nimodipine group and
43 in the placebo group had a disability score of 7
(severe impairment) at baseline. Of these patients,
13 (33%) in the nimodipine group recovered com-
pletely (disability score of 28) or had only a slight
impairment (disability score of 21) after 28 days
compared with only six patients (14%) in the placebo
group. By contrast, in the nimodipine group only 10
patients had a severe impairment after 28 days of
treatment and only four patients died (36%) com-
pared with 18 and 10 patients, respectively (65%), in
the placebo group.
With regard to aphasia, 33 patients in each group
had a score of 0-10 at baseline. Twenty-one patients
(64%) in the nimodipine group and eight (24%) in
the placebo group reached a score of 15-23 after 28
days of treatment.
When motor power of the affected side was eval-
uated, 14 of 40 patients (35%) in the nimodipine
group with an unfavorable score (0-4 points: sum of
upper and lower limb) at baseline reached a final
score of 8-10 points, while only eight of 48 patients
(17%) in the placebo group in the same condition at
baseline improved.
No differences in mean systolic or diastolic blood
pressure or heart rate were observed between groups
(Figures 3-5).
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TABLE 5. Relative Change in Neurologic Deficit After 28 Days for 123 Stroke Patients Valid for Efficacy Analysis by
Mathew Scale Sum Score at Baseline
Relative change
Death
Deterioration
Improvement
0-25%
25-50%
>50%
<65
Nimodipine
(«=«)
6
1
14
8
19
Placebo
(/i=48)
10
1
14
19
4
Score
>65
Nimodipine
(« = 10)
0
0
2
1
7
Placebo
(»=17)
0
1
2
2
12
Total
16
3
32
30
42
Data are number of patients.
Adverse reactions in the 164 patients initially
entered into the study were also recorded. Gastroin-
testinal bleeding occurred in two patients in each
group. Four nimodipine-treated patients suffered
adverse effects considered to be probably or possibly
related to therapy. These cases included one patient
with gastrointestinal bleeding who had received dex-
amethasone concomitantly, one patient with a vagal
reaction, one patient with a maculopapulous skin
reaction, and another patient with abdominal
distension.
Cumulative
proportion
of patients
l%]
100-t
90-
80
70
60-
50-
40
30
20-
10
0
+100
normal
P = 0.025
relative change
in deficit [%]
50
*
25 0 -25
unchanged
improvement deterioration
-50 -75 -100
dead
FIGURE 2. Cumulative frequency diagram of relative change
in neurologic deficit for 96 stroke patients valid for efficacy
analysis with Mathew Scale sum score at baseline of <65. —,
Nimodipine group (n=48); , placebo group (n=48).
Discussion
Some aspects of the design of a clinical trial of
acute ischemic cerebral infarction must be taken into
account before undertaking the clinical study. The
inclusion criteria must be sufficiently permissive to
allow a reasonable rate of patient recruitment while
being sufficiently restrictive to ensure homogeneity of
the sample. Another difficulty to bear in mind is the
selection and definition of the evaluation criteria.
Although much has been discussed and many scales
have been proposed, studies designed to validate the
evaluation system have only recently been carried
out.10 We used the Mathew Scale because it is a
relatively quick and simple method of assessing neu-
rologic status and, particularly, because it was used in
the first double-blind, placebo-controlled trial of
nimodipine reported in the literature.8
[mm Hg]
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FIGURE 3. Graph of mean±SD systolic blood pressure
during treatment period for 123 stroke patients valid for
efficacy analysis. • , Nimodipine group (n=58); O, placebo
group (n=65).
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FIGURE 4. Graph of mean±SD diastolic blood pressure
during treatment period for 123 stroke patients valid for
efficacy analysis. • , Nimodipine group (n=58); O, placebo
group (n=65).
A relevant problem arises when describing the
outcome of a study using statistical methods based on
mean values. The mean disability of survivors
improves, whereas more severely ill patients die and
do not contribute to the final mean. This indicates
that a single study is not necessarily adequate to show
primary effects in both mortality and neurologic
outcome at the same time; if spontaneous mortality is
high and if active treatment reduces it significantly,
[/min]
100-1
95-
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70-
65-
—•<
*''•* I i i i i i i <i I I i i I i i i i i i i i i i i i i i i i
0 7 14 21 28
DAY
FIGURE 5. Graph of mean±SD heart rate during treatment
period for 123 stroke patients valid for efficacy analysis. • ,
Nimodipine group (n=58); o, placebo group (n=65).
the treated group is then soon at a disadvantage11
from the standpoint of neurologic or functional
recovery. This was taken into account by our trans-
formation of the Mathew Scale scores.
Concomitant medication must also be considered.
Because no participating center used a standard
therapy for treating acute cerebral infarction, the
protocol allowed the concomitant administration of
any drug judged indicated for the complications
frequently seen in these patients. Concomitant ther-
apies were similarly distributed in both groups; it is
very unlikely that concomitant therapies contributed
to the differences in favor of nimodipine.
A priori prognostic stratification of patients in
clinical trials of cerebral infarction is often recom-
mended. We used no randomization stratification
according to severity, but the baseline neurologic
impairment was similar in both groups (as shown in
Table 3). At the time of analysis of neurologic
outcome, two categories of patients were considered
(those with a Mathew Scale sum score of <65 and
>65 at baseline). This categorization was chosen
because previous observations78 have shown that
nimodipine is better than placebo only in patients with
an at least moderate-to-severe baseline neurologic
deficit; we confirmed this restriction. The restriction of
nimodipine's efficacy could be explained by the fact
that patients with a relatively normal baseline neuro-
logic status (Mathew Scale sum score of >65) have a
spontaneous rate of recovery so high that no addi-
tional effect due to nimodipine therapy can be mea-
sured. In patients with a baseline Mathew Scale sum
score of <65, the administration of nimodipine had a
significant effect on neurologic outcome. This benefi-
cial effect was clinically measurable and is similar to
that reported by Gelmers et al8 in the first double-
blind placebo-controlled trial of oral nimodipine in
patients with acute cerebral infarction.
Nimodipine-treated patients showed a trend toward
a lower 28-day mortality rate, particularly in the
subgroup with moderate-to-very severe neurologic
deficit at baseline. However, and in contrast to the
findings of Gelmers et al,8 this difference in mortality
rate was not significant.
It is worth noting that nimodipine had no significant
effect on systemic hemodynamics, which is in agree-
ment with the findings of other clinical trials.1213
The mechanism responsible for the beneficial
effect of nimodipine in patients with acute ischemic
cerebral infarction is not completely understood and
may be multiple. On one hand, nimodipine prevents
the postischemic reduction of cerebral blood flow
after transient interruption of cerebral perfusion
seen in animals.14-15 Some experimental evidence
shows that the immediate failure of basic neuronal
functions depends heavily on residual blood flow.
Total failure of these functions occurs below a critical
blood flow threshold,16 while at higher blood flows
cerebral infarction occurs after a certain time.17
The ischemic cerebral territory that shows a border-
line blood flow was named the ischemic penumbra.18
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Complicated phenomena that tend to reinforce the
effects of the initial ischemic insult and biochemical
reactions that eventually lead to neuronal death occur
in this area.19 A recently reported dysregulation of
calcium homeostasis in ischemic cells appears to be
the final pathway responsible for cell death.20 Apart
from its vascular effects, the demonstration of specific
binding sites for [3H]nimodipine in human cerebral
tissue21 and the behavioral changes observed in ani-
mals treated with nimodipine22 suggest that this
agent acts directly on the cerebral tissue. In our trial,
differences in the causes of death between groups
may be relevant, with more deaths due to central
nervous system complications, particularly cerebral
edema, in the placebo group. Whether this finding is
related to the mechanism of action of nimodipine or
to any other possible explanation remains at present
merely speculative.
Although there is evidence that cerebral ischemia
and especially the ischemic penumbra are susceptible
to therapeutic intervention,2 the time interval after
the acute ischemic event during which such interven-
tion is useful in humans is not clear. However, an
intuitive and reasonable inference is that sooner is
probably better. The maximum interval of 48 hours
that we used was chosen because it was clinically
feasible and similar to that used in other studies.78
Whether our results obtained with nimodipine can be
extrapolated to other calcium antagonists remains to
be elucidated since, as far as we know, no controlled
clinical trials with other agents of this group have yet
been reported.
Neurologic outcome after 28 days of therapy did
not differ between groups. However, when only those
patients most likely to benefit from any intervention
(those with a Mathew Scale sum score of <65 at
baseline) were analyzed separately post hoc, the
nimodipine group had a significantly better neuro-
logic outcome. This result suggests that some patients
with acute ischemic stroke would benefit from treat-
ment with nimodipine tablets.
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